Published in Ophthalmology on November 07, 2006
Ocular Hypertension Treatment Study (OHTS) (OHTS) | NCT00000125
The African Descent and Glaucoma Evaluation Study (ADAGES): design and baseline data. Arch Ophthalmol (2009) 2.59
Prediction of functional loss in glaucoma from progressive optic disc damage. Arch Ophthalmol (2009) 2.53
Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol (2010) 2.14
Diagnostic tools for glaucoma detection and management. Surv Ophthalmol (2008) 1.58
Glaucoma: genes, phenotypes, and new directions for therapy. J Clin Invest (2010) 1.39
Comparison of HRT-3 glaucoma probability score and subjective stereophotograph assessment for prediction of progression in glaucoma. Invest Ophthalmol Vis Sci (2008) 1.25
Adjusting intraocular pressure for central corneal thickness does not improve prediction models for primary open-angle glaucoma. Ophthalmology (2011) 1.23
Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology (2007) 1.18
Quantitative evaluation of anterior segment parameters in the era of imaging. Trans Am Ophthalmol Soc (2007) 1.15
Developing the clinical components of a complex intervention for a glaucoma screening trial: a mixed methods study. BMC Med Res Methodol (2011) 1.12
Predicting the onset of glaucoma: the confocal scanning laser ophthalmoscopy ancillary study to theOcular Hypertension Treatment Study. Ophthalmology (2010) 1.05
Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group. Invest Ophthalmol Vis Sci (2012) 1.03
Predicting progression in glaucoma suspects with longitudinal estimates of retinal ganglion cell counts. Invest Ophthalmol Vis Sci (2013) 1.00
Evaluation of progressive neuroretinal rim loss as a surrogate end point for development of visual field loss in glaucoma. Ophthalmology (2013) 0.97
Predicting development of proliferative diabetic retinopathy. Diabetes Care (2012) 0.95
Relationship between pattern electroretinogram, standard automated perimetry, and optic nerve structural assessments. J Glaucoma (2009) 0.93
Distribution of central corneal thickness and its association with ocular parameters in a large central European cohort: the Gutenberg health study. PLoS One (2013) 0.92
Strategies for improving early detection of glaucoma: the combined structure-function index. Clin Ophthalmol (2014) 0.91
Is corneal thickness an independent risk factor for glaucoma? Ophthalmology (2012) 0.91
Is 24-hour intraocular pressure monitoring necessary in glaucoma? Semin Ophthalmol (2013) 0.91
Oral microbiome link to neurodegeneration in glaucoma. PLoS One (2014) 0.89
Development of a risk score for geographic atrophy in complications of the age-related macular degeneration prevention trial. Ophthalmology (2011) 0.88
A new method for determining physician decision thresholds using empiric, uncertain recommendations. BMC Med Inform Decis Mak (2010) 0.87
The accuracy and clinical application of predictive models for primary open-angle glaucoma in ocular hypertensive individuals. Ophthalmology (2008) 0.85
Determinants of agreement between the confocal scanning laser tomograph and standardized assessment of glaucomatous progression. Ophthalmology (2010) 0.84
Predicting progression of glaucoma from rates of frequency doubling technology perimetry change. Ophthalmology (2013) 0.84
For which glaucoma suspects is it appropriate to initiate treatment? Ophthalmology (2009) 0.84
Central corneal thickness, lamina cribrosa and peripapillary scleral histomorphometry in non-glaucomatous Chinese eyes. Graefes Arch Clin Exp Ophthalmol (2010) 0.82
Biomarkers of primary open-angle glaucoma. Expert Rev Ophthalmol (2010) 0.81
The effect of changes in intraocular pressure on the risk of primary open-angle glaucoma in patients with ocular hypertension: an application of latent class analysis. BMC Med Res Methodol (2012) 0.81
Predicting Development of Glaucomatous Visual Field Conversion Using Baseline Fourier-Domain Optical Coherence Tomography. Am J Ophthalmol (2015) 0.80
Clinical characteristics and current treatment of glaucoma. Cold Spring Harb Perspect Med (2014) 0.79
[Medicinal glaucoma therapy. What can we learn from large randomized clinical trials?]. Ophthalmologe (2013) 0.79
Incorporating mortality risk into estimates of 5-year glaucoma risk. Am J Ophthalmol (2009) 0.79
Automatic glaucoma diagnosis through medical imaging informatics. J Am Med Inform Assoc (2013) 0.78
Estimating the risk of developing glaucoma. Open Ophthalmol J (2009) 0.78
A validated risk calculator to assess risk and rate of visual field progression in treated glaucoma patients. Invest Ophthalmol Vis Sci (2012) 0.78
Ahmed glaucoma valve implant: surgical technique and complications. Clin Ophthalmol (2017) 0.77
Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. Prog Retin Eye Res (2016) 0.77
Frequency Doubling Technology vs Standard Automated Perimetry in Ocular Hypertensive Patients. Open Ophthalmol J (2009) 0.77
Effect of dorzolamide/timolol combination on the visual field in glaucoma. Clin Ophthalmol (2014) 0.77
Noninvasive intraocular pressure monitoring: current insights. Clin Ophthalmol (2015) 0.77
A Joint Model for Prognostic Effect of Biomarker Variability on Outcomes: long-term intraocular pressure (IOP) fluctuation on the risk of developing primary open-angle glaucoma (POAG). JP J Biostat (2011) 0.77
Stratification of phaco-trabectome surgery results using a glaucoma severity index in a retrospective analysis. BMC Ophthalmol (2017) 0.77
Glaucoma history and risk factors. J Optom (2016) 0.76
Spectral analysis of intraocular pressure pulse wave in ocular hypertensive and primary open angle glaucoma patients. Indian J Ophthalmol (2016) 0.75
Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure. Clin Ophthalmol (2014) 0.75
The usefulness of CorvisST Tonometry and the Ocular Response Analyzer to assess the progression of glaucoma. Sci Rep (2017) 0.75
Expression of glucose transporters in the prelaminar region of the optic-nerve head of the pig as determined by immunolabeling and tissue culture. PLoS One (2015) 0.75
Stereo Photo Measured ONH Shape Predicts Development of POAG in Subjects With Ocular Hypertension. Invest Ophthalmol Vis Sci (2015) 0.75
Clinical trials - more than an assessment of treatment effect: LXV Edward Jackson Memorial Lecture. Am J Ophthalmol (2009) 0.75
Baseline factors predicting the risk of conversion from ocular hypertension to primary open-angle glaucoma during a 10-year follow-up. Eye (Lond) (2016) 0.75
Risk assessment for glaucoma. Open Ophthalmol J (2009) 0.75
[Differentiation of ocular hypertension]. Ophthalmologe (2016) 0.75
Risk of Ocular Hypertension in Adults with Noninfectious Uveitis. Ophthalmology (2017) 0.75
Effects of Vitrectomy and Lensectomy on Older Rhesus Macaques: Oxygen Distribution, Antioxidant Status, and Aqueous Humor Dynamics. Invest Ophthalmol Vis Sci (2017) 0.75
[Arguments for prophylactic therapy of ocular hypertension]. Ophthalmologe (2011) 0.75
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (1996) 46.18
Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA (2001) 17.91
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89
Number of people with glaucoma worldwide. Br J Ophthalmol (1996) 14.31
Evaluating the yield of medical tests. JAMA (1982) 14.05
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 11.38
Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA (1991) 9.42
The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol (1981) 7.05
Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med (1991) 4.73
Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol (1995) 4.09
The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol (1994) 3.92
The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology (1999) 3.87
Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology (2004) 3.66
The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol (2001) 3.31
The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol (1999) 3.30
Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol (2001) 3.20
Results of the European Glaucoma Prevention Study. Ophthalmology (2005) 2.91
National survey of the prevalence and risk factors of glaucoma in St. Lucia, West Indies. Part I. Prevalence findings. Ophthalmology (1989) 2.78
Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci (1997) 2.75
Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology (2000) 2.75
Prevalence and causes of visual impairment in The Barbados Eye Study. Ophthalmology (2001) 2.70
Prevalence of glaucoma in a rural East African population. Invest Ophthalmol Vis Sci (2000) 2.50
Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. Arch Ophthalmol (1980) 2.28
Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma. Arch Ophthalmol (2005) 2.10
Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol (1994) 2.06
Five-year incidence of open-angle glaucoma: the visual impairment project. Ophthalmology (2002) 2.05
Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology (2006) 2.01
A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology (1989) 1.83
Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol (2006) 1.80
Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci (2003) 1.79
Open-angle glaucoma and older-onset diabetes. The Beaver Dam Eye Study. Ophthalmology (1994) 1.74
Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population. The Rotterdam Study. Ophthalmology (1996) 1.65
Validation, calibration, revision and combination of prognostic survival models. Stat Med (2000) 1.62
A comparison of treated and untreated glaucoma suspects. Ophthalmology (1991) 1.61
Open-angle glaucoma and systemic hypertension: the blue mountains eye study. J Glaucoma (2004) 1.56
Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology (2005) 1.51
Five-year risk of progression of ocular hypertension to primary open angle glaucoma. A population-based study. Indian J Ophthalmol (2003) 1.49
Multivariate analysis of the risk of glaucomatous visual field loss. Arch Ophthalmol (1979) 1.44
A long-term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. J Glaucoma (2005) 1.25
Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial. Arch Ophthalmol (1989) 1.22
Prognostic indicators in ocular hypertension. Arch Ophthalmol (1974) 1.21
Multivariate analysis in glaucoma. Use of discriminant analysis in predicting glaucomatous visual field damage. Arch Ophthalmol (1981) 1.13
The European glaucoma prevention study design and baseline description of the participants. Ophthalmology (2002) 1.05
Risk of glaucoma in ocular hypertension with and without pseudoexfoliation. Ophthalmology (2005) 0.94
Elevated intraocular pressure and pseudoexfoliation of the lens capsule as risk factors for chronic open-angle glaucoma. A population-based five-year follow-up study. Acta Ophthalmol (Copenh) (1993) 0.90
Corneal thickness and functional damage in patients with ocular hypertension. Eur J Ophthalmol (2005) 0.89
Prognostic factors in the development of manifest open angle glaucoma. A long-term follow-up study of hypertensive and normotensive eyes. Acta Ophthalmol (Copenh) (1986) 0.87
Risk factors in ocular hypertension. Eur J Ophthalmol (1998) 0.85
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 11.38
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA (2006) 9.55
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Incidence of diabetes in youth in the United States. JAMA (2007) 8.70
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22
Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS (2003) 8.05
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27
The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics (2006) 7.19
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med (2002) 6.92
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 6.84
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med (2004) 6.42
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation (2006) 5.97
Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med (2011) 5.94
A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 5.64
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA (2004) 5.34
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33
The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA (2004) 4.85
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA (2013) 4.81
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA (2003) 4.77
Free access to Landsat imagery. Science (2008) 4.75
Trends in cardiovascular complications of diabetes. JAMA (2004) 4.74
Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA (2004) 4.63
Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med (2008) 4.63
Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation (2009) 4.62
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 4.62
A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med (2008) 4.61
Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke (2004) 4.56
On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med (2011) 4.34
Estimating treatment effects using observational data. JAMA (2007) 4.12
Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation (2003) 4.09
Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation (2005) 4.08
Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study. Am J Hum Genet (2002) 4.07
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation (2007) 3.99
Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care (2002) 3.96
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80
Hybrid origin of SIV in chimpanzees. Science (2003) 3.75
Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology (2006) 3.69
Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care (2006) 3.67
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005) 3.64
Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. J Virol (2002) 3.58
Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med (2010) 3.57
Long-term trends in the incidence of heart failure after myocardial infarction. Circulation (2008) 3.52
Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension (2004) 3.51
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol (2006) 3.48
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis (2007) 3.46
Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation (2006) 3.41
Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study. J Clin Endocrinol Metab (2010) 3.39
Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care (2008) 3.33
C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med (2005) 3.31
Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol (2004) 3.27
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med (2014) 3.25
C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation (2004) 3.25
Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol (2012) 3.24